Prelude Therapeutics Incorporated (PRLD)
Largest Insider Buys in Sector
PRLD Stock Price History Chart
PRLD Stock Performance
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high …
Insider Activity of Prelude Therapeutics Incorporated
Over the last 12 months, insiders at Prelude Therapeutics Incorporated have bought $0 and sold $0 worth of Prelude Therapeutics Incorporated stock.
On average, over the past 5 years, insiders at Prelude Therapeutics Incorporated have bought $42.86M and sold $3.47M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 900 shares for transaction amount of $4,779 was made by Vaddi Krishna (CEO) on 2023‑05‑25.
List of Insider Buy and Sell Transactions, Prelude Therapeutics Incorporated
| 2023-05-25 | CEO | 900 0.0019% | $5.31 | $4,779 | -27.80% | |||
| 2023-05-24 | CEO | 1,000 0.002% | $5.01 | $5,011 | -26.36% | |||
| 2023-05-24 | Chief Legal Officer, Corp Sec. | 2,400 0.0053% | $5.39 | $12,936 | -26.36% | |||
| 2023-05-23 | CEO | 11,856 0.0257% | $5.63 | $66,749 | -30.28% | |||
| 2023-05-23 | Chief Financial Officer | 5,000 0.0106% | $5.50 | $27,500 | -30.28% | |||
| 2023-05-22 | 869,565 1.9148% | $5.75 | $5M | -30.53% | ||||
| 2023-05-22 | 869,565 1.9148% | $5.75 | $5M | -30.53% | ||||
| 2023-04-06 | Sale | President, CMO | 13,280 0.0276% | $6.12 | $81,274 | -36.53% | ||
| 2022-12-20 | CEO | 19,188 0.0417% | $5.13 | $98,446 | -6.63% | |||
| 2022-12-08 | Chief Financial Officer | 10,000 0.0199% | $4.76 | $47,600 | -1.98% | |||
| 2022-06-01 | Chief Financial Officer | 10,000 0.0213% | $4.23 | $42,300 | +48.69% | |||
| 2021-12-15 | Sale | EVP, Chief of Clinical Affairs | 28,751 0.061% | $13.00 | $373,763 | -48.80% | ||
| 2021-12-14 | EVP, Head of Chemistry | 4,000 0.0085% | $11.60 | $46,400 | -42.68% | |||
| 2021-12-13 | EVP, Head of Chemistry | 4,000 0.0087% | $12.12 | $48,480 | -43.56% | |||
| 2021-11-16 | Sale | EVP, Chief of Clinical Affairs | 28,751 0.0619% | $15.88 | $456,532 | -54.90% | ||
| 2021-10-05 | Sale | Chief Medical Officer | 15,000 0.0336% | $30.96 | $464,350 | -74.15% | ||
| 2021-09-07 | Sale | Chief Medical Officer | 15,000 0.0314% | $36.69 | $550,283 | -77.25% | ||
| 2021-09-02 | Sale | EVP and Chief of Business Oper | 17,000 0.0396% | $41.68 | $708,493 | -77.31% | ||
| 2021-08-27 | Sale | Chief Scientific Officer | 6,014 0.0124% | $35.91 | $215,967 | -76.42% | ||
| 2021-08-26 | Sale | Chief Scientific Officer | 1,700 0.0038% | $35.19 | $59,819 | -74.05% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | 10119756 18.3878% | $0.95 | 5 | 0 | <0.0001% | |
| Bonita David P | 10119756 18.3878% | $0.95 | 5 | 0 | +9.05% | |
| BAKER BROS. ADVISORS LP | 5212371 9.471% | $0.95 | 4 | 0 | +34.76% | |
| Vaddi Krishna | CEO | 1067275 1.9393% | $0.95 | 4 | 0 | <0.0001% |
| Combs Andrew | EVP, Head of Chemistry | 268380 0.4877% | $0.95 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| OrbiMed | $51.71M | 19.86 | 10.91M | 0% | +$0 | 0.4 | |
| Baker Bros Advisors LP | $47.99M | 18.43 | 10.12M | 0% | +$0 | 0.35 | |
| Deerfield Management | $19.59M | 7.52 | 4.13M | 0% | +$0 | 0.05 | |
| Boxer Capital, LLC | $12.17M | 4.68 | 2.57M | 0% | +$0 | 0.25 | |
| BlackRock | $5.2M | 2 | 1.1M | +0.17% | +$8,934.90 | <0.0001 |